Acta Pharmaceutica Sinica B,
Год журнала:
2023,
Номер
13(7), С. 2877 - 2896
Опубликована: Фев. 24, 2023
The
ongoing
coronavirus
disease
2019
(COVID-19)
pandemic
has
boosted
the
development
of
antiviral
research.
Microfluidic
technologies
offer
powerful
platforms
for
diagnosis
and
drug
discovery
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
discovery.
In
this
review,
we
introduce
structure
SARS-CoV-2
basic
knowledge
microfluidic
design.
We
discuss
application
devices
in
based
on
detecting
viral
nucleic
acid,
antibodies,
antigens.
highlight
contribution
lab-on-a-chip
to
manufacturing
point-of-care
equipment
accurate,
sensitive,
low-cost,
user-friendly
virus-detection
devices.
then
investigate
efforts
organ-on-a-chip
lipid
nanoparticles
(LNPs)
synthesizing
chips
screening
mRNA
vaccine
preparation.
contribute
research
provide
tools
future
outbreaks.
Signal Transduction and Targeted Therapy,
Год журнала:
2023,
Номер
8(1)
Опубликована: Дек. 13, 2023
With
the
development
and
regulatory
approval
of
immune
checkpoint
inhibitors
adoptive
cell
therapies,
cancer
immunotherapy
has
undergone
a
profound
transformation
over
past
decades.
Recently,
therapeutic
vaccines
have
shown
promise
by
eliciting
de
novo
T
responses
targeting
tumor
antigens,
including
tumor-associated
antigens
tumor-specific
antigens.
The
objective
was
to
amplify
diversify
intrinsic
repertoire
cells.
However,
complete
realization
these
capabilities
remains
an
ongoing
pursuit.
Therefore,
we
provide
overview
current
landscape
in
this
review.
range
antigen
selection,
delivery
systems
strategic
nuances
underlying
effective
presentation
pioneered
vaccine
design.
Furthermore,
review
addresses
status
clinical
trials
discusses
their
strategies,
focusing
on
immunogenicity
anti-tumor
efficacy
assessment.
attempts
toward
developing
not
yielded
breakthrough
outcomes
due
significant
challenges,
microenvironment
suppression,
optimal
candidate
identification,
response
evaluation,
manufacturing
acceleration.
field
is
poised
overcome
hurdles
improve
patient
future
acknowledging
complexities
persistently
striving
surmount
inherent
constraints.
Cancer Cell,
Год журнала:
2024,
Номер
42(2), С. 180 - 197
Опубликована: Фев. 1, 2024
The
past
decade
has
witnessed
significant
advances
in
the
systemic
treatment
of
advanced
hepatocellular
carcinoma
(HCC).
Nevertheless,
newly
developed
strategies
have
not
achieved
universal
success
and
HCC
patients
frequently
exhibit
therapeutic
resistance
to
these
therapies.
Precision
represents
a
paradigm
shift
cancer
recent
years.
This
approach
utilizes
unique
molecular
characteristics
individual
patient
personalize
modalities,
aiming
maximize
efficacy
while
minimizing
side
effects.
Although
precision
shown
multiple
types,
its
application
remains
infancy.
In
this
review,
we
discuss
key
aspects
HCC,
including
biomarkers,
classifications,
heterogeneity
tumor
microenvironment.
We
also
propose
future
directions,
ranging
from
revolutionizing
current
methodologies
personalizing
therapy
through
functional
assays,
which
will
accelerate
next
phase
advancements
area.
Theranostics,
Год журнала:
2022,
Номер
12(14), С. 6422 - 6436
Опубликована: Янв. 1, 2022
Rationale:
Messenger
RNA
(mRNA)
vaccine
outperforms
other
kinds
of
cancer
immunotherapy
due
to
its
high
response
rates,
easy
preparation,
and
wide
applicability,
which
is
considered
as
one
the
most
promising
forms
next-generation
therapies.However,
inherent
instability
insufficient
protein
expression
duration
mRNA
limit
efficacy
widespread
application
vaccine.Methods:
Here,
we
first
tested
possibility
a
novel
circular
(circRNA)
platform
for
compare
with
linear
RNA.Then,
developed
lipid
nanoparticle
(LNP)
system
circRNA
delivery
in
vitro
vivo.Next,
innate
adaptive
immune
circRNA-LNP
complex
was
evaluated
vivo.The
anti-tumor
further
confirmed
three
tumor
models.Finally,
combination
therapy
adoptive
cell
transfer
investigated
late-stage
model.
Results:We
successfully
increased
stability
by
circularizing
molecules
form
highly
stable
exhibited
durable
ability.By
encapsulating
antigen-coding
LNP
enabling
vivo
expression,
established
platform,
capable
triggering
robust
activation
showed
superior
multiple
mouse
models.Conclusions:
Overall,
our
provides
prospect
development
vaccines
range
hard-to-treat
malignancies.
Signal Transduction and Targeted Therapy,
Год журнала:
2023,
Номер
8(1)
Опубликована: Сен. 11, 2023
Abstract
CircRNAs
are
a
class
of
single-stranded
RNAs
with
covalently
linked
head-to-tail
topology.
In
the
decades
since
its
initial
discovery,
their
biogenesis,
regulation,
and
function
have
rapidly
disclosed,
permitting
better
understanding
adoption
them
as
new
tools
for
medical
applications.
With
development
biotechnology
molecular
medicine,
artificial
circRNAs
been
engineered
novel
vaccines
disease
treatment
prevention.
Unlike
linear
mRNA
vaccine
which
applications
were
limited
by
instability,
inefficiency,
innate
immunogenicity,
circRNA
incorporate
internal
ribosome
entry
sites
(IRESs)
open
reading
frame
(ORF)
provides
an
improved
approach
to
RNA-based
vaccination
safety,
stability,
simplicity
manufacture,
scalability.
However,
at
early
stage,
optimization,
delivery
require
further
evaluation.
this
review,
we
comprehensively
describe
vaccine,
including
history
superiority.
We
also
summarize
discuss
current
methodological
research
preparation,
design,
synthesis,
purification.
Finally,
highlight
options
potential
in
diseases
Considering
unique
high
low
protein/peptide-coding
capacity
special
closed-loop
construction,
circRNA-based
therapeutic
platforms
may
superior
application
prospects
broad
range
diseases.
Frontiers in Immunology,
Год журнала:
2022,
Номер
13
Опубликована: Дек. 14, 2022
Immunotherapy
has
emerged
as
a
breakthrough
strategy
in
cancer
treatment.
mRNA
vaccines
are
an
attractive
and
powerful
immunotherapeutic
platform
against
because
of
their
high
potency,
specificity,
versatility,
rapid
large-scale
development
capability,
low-cost
manufacturing
potential,
safety.
Recent
technological
advances
vaccine
design
delivery
have
accelerated
vaccines’
clinical
application.
In
this
review,
we
present
various
platforms
with
focus
on
nucleic
acid
vaccines.
We
discuss
rational
optimization
strategies
for
development.
highlight
the
available
lipid
nanoparticles
(LNPs)
based
systems.
Finally,
limitations
future
challenges.
Pharmaceutics,
Год журнала:
2022,
Номер
14(12), С. 2682 - 2682
Опубликована: Дек. 1, 2022
Messenger
RNA
(mRNA),
which
is
composed
of
ribonucleotides
that
carry
genetic
information
and
direct
protein
synthesis,
transcribed
from
a
strand
DNA
as
template.
On
this
basis,
mRNA
technology
can
take
advantage
the
body's
own
translation
system
to
express
proteins
with
multiple
functions
for
treatment
various
diseases.
Due
advancement
synthesis
purification,
modification
sequence
optimization
technologies,
emerging
lipid
nanomaterials
other
delivery
systems,
therapeutic
regimens
are
becoming
clinically
feasible
exhibit
significant
reliability
in
stability,
efficiency,
controlled
immunogenicity.
Lipid
nanoparticles
(LNPs),
currently
leading
non-viral
vehicles,
have
made
many
exciting
advances
clinical
part
COVID-19
vaccines
therefore
potential
accelerate
gene
drugs.
Additionally,
due
their
small
size,
biocompatibility,
biodegradability,
LNPs
effectively
deliver
nucleic
acids
into
cells,
particularly
important
current
regimens.
Therefore,
cutting-edge
LNP@mRNA
hold
great
promise
cancer
vaccines,
infectious
disease
prevention,
replacement
therapy,
editing,
rare
treatment.
To
shed
more
lights
on
LNP@mRNA,
paper
mainly
discusses
rational
choosing
vectors
mRNA,
general
rules
LNP
preparation,
parameters
affecting
efficiency
finally
summarizes
research
status
well
challenges.
The
latest
progress
diseases
such
oncological,
cardiovascular,
also
given.
Finally,
future
applications
perspectives
generally
introduced.
Clinical and Translational Medicine,
Год журнала:
2023,
Номер
13(8)
Опубликована: Авг. 1, 2023
Abstract
Messenger
ribonucleic
acid
(mRNA)
vaccines
are
a
relatively
new
class
of
that
have
shown
great
promise
in
the
immunotherapy
wide
variety
infectious
diseases
and
cancer.
In
past
2
years,
SARS‐CoV‐2
mRNA
contributed
tremendously
against
SARS‐CoV2,
which
has
prompted
arrival
vaccine
research
boom,
especially
cancer
vaccines.
Compared
with
conventional
vaccines,
significant
advantages,
including
efficient
production
protective
immune
responses,
low
side
effects
lower
cost
acquisition.
this
review,
we
elaborated
on
development
as
well
potential
biological
mechanisms
latest
progress
various
tumour
treatments,
discussed
challenges
future
directions
for
field.
